Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma

PURPOSE: Tyrosine kinase inhibitors (TKI) have poor efficacy in patients with glioblastoma (GBM). Here, we studied whether this is predominantly due to restricted blood–brain barrier penetration or more to biological characteristics of GBM. PATIENTS AND METHODS: Tumor drug concentrations of the TKI...

Descripción completa

Detalles Bibliográficos
Autores principales: van Linde, Myra E., Labots, Mariette, Brahm, Cyrillo G., Hovinga, Koos E., De Witt Hamer, Philip C., Honeywell, Richard J., de Goeij-de Haas, Richard, Henneman, Alex A., Knol, Jaco C., Peters, Godefridus J., Dekker, Henk, Piersma, Sander R., Pham, Thang V., Vandertop, William P., Jiménez, Connie R., Verheul, Henk M.W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365363/
https://www.ncbi.nlm.nih.gov/pubmed/35165100
http://dx.doi.org/10.1158/1078-0432.CCR-21-1933

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365363/
https://www.ncbi.nlm.nih.gov/pubmed/35165100
http://dx.doi.org/10.1158/1078-0432.CCR-21-1933

Ejemplares similares